Last reviewed · How we verify
Desloratadine / Betamethasone in fixed dose
Desloratadine / Betamethasone in fixed dose is a Antihistamine / Corticosteroid combination Small molecule drug developed by Laboratorios Silanes S.A. de C.V.. It is currently in Phase 3 development for Allergic rhinitis, Allergic dermatitis, Urticaria. Also known as: DESLORA / BETA.
Desloratadine blocks histamine H1 receptors to reduce allergic symptoms, while betamethasone is a corticosteroid that suppresses inflammatory and immune responses.
Desloratadine blocks histamine H1 receptors to reduce allergic symptoms, while betamethasone is a corticosteroid that suppresses inflammatory and immune responses. Used for Allergic rhinitis, Allergic dermatitis, Urticaria.
At a glance
| Generic name | Desloratadine / Betamethasone in fixed dose |
|---|---|
| Also known as | DESLORA / BETA |
| Sponsor | Laboratorios Silanes S.A. de C.V. |
| Drug class | Antihistamine / Corticosteroid combination |
| Target | H1 receptor / Glucocorticoid receptor |
| Modality | Small molecule |
| Therapeutic area | Immunology / Allergy |
| Phase | Phase 3 |
Mechanism of action
Desloratadine is a selective H1-receptor antagonist that prevents histamine-mediated allergic reactions without significant central nervous system penetration. Betamethasone is a glucocorticoid that reduces inflammation by suppressing cytokine production and immune cell activation. The fixed combination targets both the acute histamine-driven symptoms and the underlying inflammatory cascade in allergic conditions.
Approved indications
- Allergic rhinitis
- Allergic dermatitis
- Urticaria
Common side effects
- Headache
- Pharyngitis
- Somnolence
- Adrenal suppression (with prolonged corticosteroid use)
- Local irritation at application site
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Desloratadine / Betamethasone in fixed dose CI brief — competitive landscape report
- Desloratadine / Betamethasone in fixed dose updates RSS · CI watch RSS
- Laboratorios Silanes S.A. de C.V. portfolio CI
Frequently asked questions about Desloratadine / Betamethasone in fixed dose
What is Desloratadine / Betamethasone in fixed dose?
How does Desloratadine / Betamethasone in fixed dose work?
What is Desloratadine / Betamethasone in fixed dose used for?
Who makes Desloratadine / Betamethasone in fixed dose?
Is Desloratadine / Betamethasone in fixed dose also known as anything else?
What drug class is Desloratadine / Betamethasone in fixed dose in?
What development phase is Desloratadine / Betamethasone in fixed dose in?
What are the side effects of Desloratadine / Betamethasone in fixed dose?
What does Desloratadine / Betamethasone in fixed dose target?
Related
- Drug class: All Antihistamine / Corticosteroid combination drugs
- Target: All drugs targeting H1 receptor / Glucocorticoid receptor
- Manufacturer: Laboratorios Silanes S.A. de C.V. — full pipeline
- Therapeutic area: All drugs in Immunology / Allergy
- Indication: Drugs for Allergic rhinitis
- Indication: Drugs for Allergic dermatitis
- Indication: Drugs for Urticaria
- Also known as: DESLORA / BETA
- Compare: Desloratadine / Betamethasone in fixed dose vs similar drugs
- Pricing: Desloratadine / Betamethasone in fixed dose cost, discount & access